SCR7

Research use only, not for human use.

SCR7 is a specific inhibitor of nonhomologous end-joining (NHEJ).

SCR7 is a specific inhibitor of nonhomologous end-joining (NHEJ), blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I; inhibits NHEJ in a Ligase IV-dependent manner within cells, causes accumulation of double-strand breaks (DSBs), and activates the intrinsic apoptotic pathway; decreases cell proliferation of MCF7, A549, and HeLa with IC50 of 40, 34, and 44 uM, respectively; increases the efficacy of DSB-inducing therapeutic modalities in mouse xenografts; increases the efficiency of precise genome editing with CRISPR-Cas9 in mammalian cell lines and in mice.

SCR-7

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DNALigaseIV

Cancer

——

1533426-72-0

334.40

C18H14N4OS

>98% (HPLC)

DMSO: ≥ 45 mg/mL

O=C(C(/N=C/C1=CC=CC=C1)=C(/N=C/C2=CC=CC=C2)N3)NC3=S

4(1H)-Pyrimidinone, 2,3-dihydro-5,6-bis[(phenylmethylene)amino]-2-thioxo-

(-20℃)

With Ice Pack

≥ 2 years